Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-04: evorpacept plus pembrolizumab and chemotherapy in advanced head and neck squamous cell carcinoma
2023-508342-17-00Phase 2Completed
- Sponsor
- ALX Oncology
- Start
- May 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of evorpacept, pembrolizumab, fluorouracil, carboplatin and cisplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by ALX Oncology. Primary endpoint: Objective response rate. Started May 2024; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-508342-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508342-17-00.